Direct oral anticoagulant use in hospitalized pediatric patients: Insights from nationwide data.
Brandon BuxtonKatharina ElliottCarla SchwalmPublished in: Pediatric blood & cancer (2024)
DOACs remain infrequently utilized in pediatric patients, especially in those under 13 years old. Initiation on heparin therapy and transition to DOACs remains common, with 80.6% of DOAC patients receiving heparin during their hospitalization. While DOAC monotherapy is not currently endorsed as first-line therapy for DVT or PE in children, it is being used clinically. Further research is needed to clarify the impact of DOAC use on patient adherence, VTE recurrence, and healthcare cost.
Keyphrases
- metabolic syndrome
- direct oral anticoagulants
- venous thromboembolism
- healthcare
- young adults
- case report
- electronic health record
- combination therapy
- open label
- big data
- cross sectional
- atrial fibrillation
- randomized controlled trial
- stem cells
- type diabetes
- skeletal muscle
- mesenchymal stem cells
- growth factor
- artificial intelligence
- weight loss
- replacement therapy